This is the authors' abstract. We don't add key points for this paper.
Neurotensin receptors (nomenclature as recommended by NC-IUPHAR [39]) are activated by the endogenous tridecapeptide neurotensin (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) derived from a precursor (NTS, 30990), which also generates neuromedin N, an agonist at the NTS2 receptor. [3H]neurotensin (human, mouse, rat) and [125I]neurotensin (human, mouse, rat) may be used to label NTS1 and NTS2 receptors at 0.1-0.3 and 3-5 nM concentrations respectively.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mazella et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: